ATE366306T1 - Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b - Google Patents

Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b

Info

Publication number
ATE366306T1
ATE366306T1 AT01973455T AT01973455T ATE366306T1 AT E366306 T1 ATE366306 T1 AT E366306T1 AT 01973455 T AT01973455 T AT 01973455T AT 01973455 T AT01973455 T AT 01973455T AT E366306 T1 ATE366306 T1 AT E366306T1
Authority
AT
Austria
Prior art keywords
rank
kappa
agonists
antagonists
screening methods
Prior art date
Application number
AT01973455T
Other languages
English (en)
Inventor
William Dougall
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE366306T1 publication Critical patent/ATE366306T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT01973455T 2000-09-22 2001-09-20 Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b ATE366306T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23515700P 2000-09-22 2000-09-22

Publications (1)

Publication Number Publication Date
ATE366306T1 true ATE366306T1 (de) 2007-07-15

Family

ID=22884325

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01973455T ATE366306T1 (de) 2000-09-22 2001-09-20 Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b

Country Status (10)

Country Link
US (2) US6884598B2 (de)
EP (1) EP1368464B1 (de)
JP (1) JP4854174B2 (de)
AT (1) ATE366306T1 (de)
AU (2) AU9303001A (de)
CA (1) CA2423052C (de)
DE (2) DE01973455T1 (de)
ES (1) ES2208145T3 (de)
MX (1) MXPA03002443A (de)
WO (1) WO2002024896A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0975754B2 (de) * 1997-04-16 2016-01-06 Amgen Inc., Osteoprotegerin bindende proteine und deren rezeptoren
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
WO1998054201A1 (en) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
US20030017151A1 (en) * 2001-05-17 2003-01-23 Dougall William C. Therapeutic use of rank antagonists
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
CA2463478A1 (en) * 2001-10-12 2003-08-14 Barnes-Jewish Hospital Methods for screening osteogenic compounds
WO2003086289A2 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
WO2004029620A2 (en) * 2002-09-26 2004-04-08 Novartis Ag Screening method involving transfected primary t cells
EP1664774A4 (de) * 2003-08-29 2007-06-27 Centocor Inc Schneller weg zum erhalten von säugerzellklonen mit hoher expression unter verwendung einer methylcellulose und immunpräzipitation-screening-verfahren
US8853367B1 (en) 2004-09-15 2014-10-07 The Uab Research Foundation Compositions and methods for modulating rank activities
AR056806A1 (es) * 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
CA2627688A1 (en) * 2005-11-23 2007-05-31 E.I. Du Pont De Nemours And Company Apparatus for recycling alkane immersion liquids and methods of employment
WO2010129710A1 (en) * 2009-05-06 2010-11-11 Emory University Use of rankl to induce differentiation of microfold cells (m cells)
US8598331B2 (en) * 2009-09-28 2013-12-03 The University Of British Columbia CLDN5 mini-promoters
JP5867671B2 (ja) * 2011-03-28 2016-02-24 国立大学法人神戸大学 コンディショナルノックアウト動物
WO2013067639A1 (en) * 2011-11-07 2013-05-16 UNIVERSITé LAVAL Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
US10253330B2 (en) 2013-02-13 2019-04-09 The University Of British Columbia CLDN5 mini-promoters

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127637A (en) * 1872-06-04 Improvement in couplings for divided axles
US133170A (en) * 1872-11-19 Improvement in wheelbarrows
US159970A (en) * 1875-02-16 Improvement in sickle-heads for harvesters
US13651A (en) * 1855-10-09 Machine for making wire dish-covers
US68690A (en) * 1867-09-10 bibge
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
GB9310194D0 (en) * 1993-05-18 1993-06-30 Millenium Bioligix Inc Assessment of osteoclast activity
JPH0956805A (ja) * 1995-08-24 1997-03-04 Millennium Biologics Inc リン酸カルシウム材の薄膜製造のための改良焼結方法
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
EP1803816A3 (de) 1996-12-13 2007-09-26 Schering Corporation Zelloberflächen-Antigene aus Säugetieren und verwandte Reagenzien
US6242213B1 (en) * 1996-12-23 2001-06-05 Immunex Corporation Isolated DNA molecules encoding RANK-L
KR100496063B1 (ko) 1997-04-15 2005-06-21 산쿄 가부시키가이샤 신규단백질 및 그 제조방법
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
EP0975754B2 (de) 1997-04-16 2016-01-06 Amgen Inc., Osteoprotegerin bindende proteine und deren rezeptoren
CA2229449A1 (en) 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
WO1998054201A1 (en) 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
JPH119269A (ja) 1997-06-19 1999-01-19 Kaken Pharmaceut Co Ltd 破骨細胞系細胞
US6831057B2 (en) 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
US7019119B2 (en) 1997-12-12 2006-03-28 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
CN1318105A (zh) 1998-09-15 2001-10-17 M&E生物技术公司 负调节Osteoprotegerin配体活性的方法
AU5379200A (en) 1999-06-02 2000-12-28 Osteopharm Inc. Bone stimulating factor
US6492124B1 (en) 1999-06-11 2002-12-10 The Rockefeller University Trance activated signal transduction pathways in osteoclasts
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
AU777634B2 (en) 1999-07-28 2004-10-28 Kazuhiro Aoki Methods of inhibiting osteoclastogenesis
ATE448781T1 (de) 1999-07-28 2009-12-15 Univ Pennsylvania Methoden zur hemmung der aktivität der osteoklasten
AU6946300A (en) 1999-08-30 2001-03-26 Mayo Foundation For Medical Education And Research Use of dna encoding osteoprotegerin to prevent or inhibit metabolic bone disorders
DE60034871T2 (de) 1999-09-03 2008-01-17 Amgen Inc., Thousand Oaks Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
EP1087230A1 (de) 1999-09-24 2001-03-28 Boehringer Ingelheim International GmbH Verfahren zum Nachweis von Verbindungen nützlich in Therapie von Knochenfehlern
AUPQ314799A0 (en) 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
US6171860B1 (en) 1999-11-05 2001-01-09 Isis Pharmaceuticals, Inc. Antisense inhibition of rank expression
DK2105449T3 (da) 2000-02-23 2019-10-07 Amgen Inc Antagonistiske selektive bindemidler af osteoprotegerinbindende protein
JP2003534022A (ja) 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
WO2002016551A2 (en) 2000-08-18 2002-02-28 University Of Massachusetts Medical Center Trance regulation of chondrocyte differentiation
AU2001288342A1 (en) 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
AU2002231602A1 (en) 2001-02-09 2002-08-28 Maxygen Holdings Ltd. Rank ligand-binding polypeptides
WO2002080955A1 (en) 2001-03-22 2002-10-17 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
US20030013651A1 (en) 2001-03-22 2003-01-16 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
US20050031583A1 (en) 2001-03-23 2005-02-10 Iqbal Grewal Uses of opg to modulate immune responses
WO2002092623A1 (en) 2001-05-11 2002-11-21 Research Development Foundation INHIBITORS OF RECEPTOR ACTIVATOR OF NF-κB AND USES THEREOF
EP1389233A4 (de) 2001-05-18 2006-03-08 Smithkline Beecham Corp Zur behandlung von durch rank-ligand-vermittelten erkrankungen geeignete monoklonale antikörper gegen rank-ligand
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl

Also Published As

Publication number Publication date
EP1368464B1 (de) 2007-07-04
CA2423052A1 (en) 2002-03-28
WO2002024896A9 (en) 2002-10-03
ES2208145T3 (es) 2007-12-16
AU9303001A (en) 2002-04-02
DE60129254D1 (de) 2007-08-16
WO2002024896A3 (en) 2003-07-10
JP2004524812A (ja) 2004-08-19
US6884598B2 (en) 2005-04-26
ES2208145T1 (es) 2004-06-16
US7572594B2 (en) 2009-08-11
JP4854174B2 (ja) 2012-01-18
DE01973455T1 (de) 2004-04-22
CA2423052C (en) 2011-07-12
AU2001293030B2 (en) 2007-07-19
US20050196801A1 (en) 2005-09-08
EP1368464A2 (de) 2003-12-10
MXPA03002443A (es) 2004-12-06
US20020086312A1 (en) 2002-07-04
WO2002024896A2 (en) 2002-03-28
DE60129254T2 (de) 2008-03-13

Similar Documents

Publication Publication Date Title
ATE366306T1 (de) Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b
She et al. Synergy between anti‐endoglin (CD105) monoclonal antibodies and TGF‐β in suppression of growth of human endothelial cells
Selkirk et al. SB‐224289–a novel selective (human) 5‐HT1B receptor antagonist with negative intrinsic activity
Ling et al. Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation
Rolli et al. Activated integrin αvβ3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells
Huang et al. Surface expression of Notch1 on thymocytes: correlation with the double-negative to double-positive transition
Brixius et al. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
BR9911621A (pt) Bifenil sulfonamidas como antagonista duplos de receptor de angiotensina endotelina
DE60127656D1 (de) Integrin antagonisten
Lü et al. Syntaxin 1A supports voltage-dependent inhibition of α1B Ca2+ channels by Gβγ in chick sensory neurons
DE69819345D1 (de) Für den capsaicin rezeptor kodierende nukleinsäuresequenzen und dem capsaicin rezeptor ähnliche polypeptide und ihre verwendung
MXPA04001287A (es) Ensayo de receptor unido a proteina g.
Zhang et al. Novel functions of CCM1 delimit the relationship of PTB/PH domains
ATE466020T1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
Pregenzer et al. Characterization of ligand binding properties of the 5-HT1D receptors cloned from chimpanzee, gorilla and rhesus monkey in comparison with those from the human and guinea pig receptors
Wainscott et al. Human 5-HT1F receptor-stimulated [35S] GTPγS binding: correlation with inhibition of guinea pig dural plasma protein extravasation
DK1064018T3 (da) Anvendelsen af isolerede domæner af Type IV kollagen til at modificere celle- og vævsinteraktioner
DE69333660D1 (de) Pct-65 serotonin rezeptor
DE60130565D1 (de) Pde8a und seine verwendung
ATE395058T1 (de) Verwendung von prostanoid-ep4-rezeptor- antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten
Johnston et al. A bifunctional Gαi/Gαs modulatory peptide that attenuates adenylyl cyclase activity
Setchenska et al. Classification of β-adrenergic subtypes in immature rabbit bone marrow erythroblasts
Anderegg et al. MEL4B3, a novel mRNA is induced in skin tumors and regulated by TGF‐β and pro‐inflammatory cytokines
Aggeli et al. Myocardial structure and matrix metalloproteinases

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties